Levodopa-Induced Dyskinesia in Parkinson's Disease (eBook)
XII, 368 Seiten
Springer London (Verlag)
978-1-4471-6503-3 (ISBN)
This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from 'bench to bedside'.
Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; on going RCTs in LID and evidence-based medicine reviews of treatment options.
Levodopa-Induced Dyskinesia in Parkinson's Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees and graduate and post-graduate students.
Dr Susan Fox is Associate Professor of Neurology at Toronto Western Hospital, University Health Network and University of Toronto, Canada. She has many years' experience in preclinical models of Parkinson's disease and translational studies of novel pharmacological therapies for Parkinson's disease and dyskinesia. She has expertise in the design and running of phase II and III clinical studies in movement disorders. She has received funding from NIH, CIHR, Parkinson Society Canada and Michael J Fox Foundation for research into PD. She has published over 120 peer reviewed papers, reviews and book chapters in the field and is a regular speaker at national and international conferences. Dr Fox is an active member of the International Parkinson and Movement Disorder Society (MDS). She is current co-editor of the MDS website and chair of the MDS evidence based medicine committee on reviews of treatments for movement disorders.
Jonathan Brotchie, PhD, is Senior Scientist at the Toronto Western Hospital, University Health Network (UHN). At UHN, he leads a research programme focused on the discovery and validation of novel therapeutic targets for Parkinson's disease and the development of therapeutics based upon those targets. The particular expertise of his group and collaborators at UHN lies in transitioning development programmes from pre-clinical efficacy to Phase II proof-of-concept. Dr Brotchie is also Founder and a Director of Atuka Ltd, a CRO specialising in the provision of support for developing therapies for neurodegenerative disorders.
This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from 'bench to bedside'.Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; on going RCTs in LID and evidence-based medicine reviews of treatment options.Levodopa-Induced Dyskinesia in Parkinson's Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees and graduate and post-graduate students.
Dr Susan Fox is Associate Professor of Neurology at Toronto Western Hospital, University Health Network and University of Toronto, Canada. She has many years’ experience in preclinical models of Parkinson's disease and translational studies of novel pharmacological therapies for Parkinson’s disease and dyskinesia. She has expertise in the design and running of phase II and III clinical studies in movement disorders. She has received funding from NIH, CIHR, Parkinson Society Canada and Michael J Fox Foundation for research into PD. She has published over 120 peer reviewed papers, reviews and book chapters in the field and is a regular speaker at national and international conferences. Dr Fox is an active member of the International Parkinson and Movement Disorder Society (MDS). She is current co-editor of the MDS website and chair of the MDS evidence based medicine committee on reviews of treatments for movement disorders.Jonathan Brotchie, PhD, is Senior Scientist at the Toronto Western Hospital, University Health Network (UHN). At UHN, he leads a research programme focused on the discovery and validation of novel therapeutic targets for Parkinson’s disease and the development of therapeutics based upon those targets. The particular expertise of his group and collaborators at UHN lies in transitioning development programmes from pre-clinical efficacy to Phase II proof-of-concept. Dr Brotchie is also Founder and a Director of Atuka Ltd, a CRO specialising in the provision of support for developing therapies for neurodegenerative disorders.
Phenomenology of Levodopa-Induced Dyskinesia.- Dyskinesia Rating Scales in Parkinson's Disease.- Epidemiology of Levodopa-Induced Dyskinesia.- Risk Factors for Levodopa-Induced Dyskinesia.- Pharmacological Treatment Options for Levodopa-Induced Dyskinesia.- Surgical Options for Levodopa-Induced Dyskinesia in Parkinson’s Disease.- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia.- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia.- Pharmacological Properties of Levodopa.- Dopamine Receptors and LID.- The Serotonergic System In Levodopa-Induced Dyskinesia.- The Opioid System in Levodopa-Induced Dyskinesia.- Glutamate Receptors and Levodopa-Induced Dyskinesia.- Cannabinoids and Levodopa-Induced Dyskinesia.- The Role of the Noradrenergic System and its Receptors In Levodopa-Induced Dyskinesia.- Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia.- New Clinical Trials for Levodopa-Induced Dyskinesia.- Preclinical Models of Levodopa-Induced Dyskinesia.- Final Thoughts: Summary and Future Therapeutic Strategies in LID.
| Erscheint lt. Verlag | 8.10.2014 |
|---|---|
| Zusatzinfo | XII, 368 p. 12 illus., 11 illus. in color. |
| Verlagsort | London |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie |
| Naturwissenschaften ► Biologie ► Humanbiologie | |
| Naturwissenschaften ► Biologie ► Zoologie | |
| Schlagworte | clinical trial • dyskinesia • Levodopa • levodopa-induced dyskinesia • Parkinsonism • Parkinson's Disease • preclinical study |
| ISBN-10 | 1-4471-6503-9 / 1447165039 |
| ISBN-13 | 978-1-4471-6503-3 / 9781447165033 |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
